Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 18 de 18
Filter
1.
Chinese Journal of Burns ; (6): 610-615, 2022.
Article in Chinese | WPRIM | ID: wpr-940968

ABSTRACT

Growth factors play an important role in wound healing, and they mainly accelerate wound healing by activating the related signal pathways. Chinese scientists have been conducting basic and clinical researches on growth factors for 30 years, with a series of growth factor drugs being developed and widely used in the treatment of burns and trauma and chronic refractory ulcers. This paper expounds the frontier progress of growth factors on wound healing from the perspectives of immunity, nerve, fat, and so on, and puts forward the further thoughts of the research team on the regulation of wound healing by growth factors.


Subject(s)
Humans , Burns/therapy , Intercellular Signaling Peptides and Proteins/therapeutic use , Signal Transduction , Wound Healing
2.
Chinese Journal of Burns ; (6): 691-696, 2022.
Article in Chinese | WPRIM | ID: wpr-940976

ABSTRACT

Wound repair is a highly coordinated and mutually regulated complex process involving various kinds of cells, extracellular matrices and cytokines. A variety of growth factors play an important regulatory role in wound healing, and it is critical to achieve effective delivery and sustained function of growth factors. In recent years, the application of biomaterials in tissue engineering has shown great potential, and the effective delivery of growth factors by biomaterials has attracted increasing attention. Based on this, this paper introduces the mechanism of related growth factors in the process of wound healing, focusing on the recent progress of biomaterial delivery of growth factors to accelerate wound healing, in order to provide new enlightenment for clinical wound treatment.


Subject(s)
Biocompatible Materials/metabolism , Extracellular Matrix/metabolism , Intercellular Signaling Peptides and Proteins/therapeutic use , Tissue Engineering , Wound Healing
3.
Arq. bras. oftalmol ; 84(3): 282-296, May-June 2021. tab, graf
Article in English | LILACS | ID: biblio-1248965

ABSTRACT

ABSTRACT This review is intended to describe the therapeutic approaches for corneal blindness, detailing the steps and elements involved in corneal wound healing. It also presents the limitations of the actual surgical and pharmacological strategies used to restore and maintain corneal transparency in terms of long-term survival and geographic coverage. In addition, we critically review the perspectives of anabolic agents, including vitamin A, hormones, growth factors, and novel promitotic and anti-inflammatory modulators, to assist corneal wound healing. We discuss the studies involving nanotechnology, gene therapy, and tissue reengineering as potential future strategies to work solely or in combination with corneal surgery to prevent or revert corneal blindness.(AU)


RESUMO O presente trabalho traz uma revisão das abordagens terapêuticas para a cegueira da córnea. O estudo detalha as etapas e os elementos envolvidos na cicatrização da córnea. Ele mostra as limitações das estratégias cirúrgicas e farmacológicas usadas para restaurar e manter a transparência da córnea em termos de sobrevida a longo prazo e alcance geográfico. As perspectivas dos agentes anabólicos, incluindo vitamina A, hormônios, fatores de crescimento e novos moduladores pró-mitóticos e anti-inflamatórios para auxiliar a cicatrização da ferida na córnea, são revisadas criticamente. Aqui, apresentamos estudos envolvendo nanotecnologia, terapia gênica e reengenharia de tecidos como possíveis estratégias futuras para atuar de maneira isolada ou combinada com a cirurgia da córnea para prevenir ou reverter a cegueira corneana.(AU)


Subject(s)
Humans , Blindness/prevention & control , Blindness/therapy , Corneal Injuries/prevention & control , Corneal Injuries/therapy , Stem Cells , Vitamin A/therapeutic use , Genetic Therapy/instrumentation , Nanotechnology/instrumentation , Intercellular Signaling Peptides and Proteins/therapeutic use , Hormones/therapeutic use , Anti-Inflammatory Agents/therapeutic use
4.
J. appl. oral sci ; 28: e20190236, 2020. tab, graf
Article in English | LILACS, BBO | ID: biblio-1090786

ABSTRACT

Abstract Objective This clinical trial sought to evaluate the clinical effectiveness of concentrated growth factor (CGF) and compare it with connective tissue graft (CTG) with coronally advanced flap (CAF) in the treatment of Miller Class I gingival recessions (GR). Methodology This split-mouth study included 74 Miller Class I isolated (24 teeth) or multiple (50 teeth) GRs in 23 jaws of 19 patients. GRs were randomly treated using CGF (test group: 37 teeth; 12 teeth in isolated GRs, 25 teeth in multiple GRs) or CTG with CAF (control group: 37 teeth;12 teeth isolated GRs, 25 teeth in multiple GRs). Clinical variables, plaque index (PI), gingival index (GI), probing depth (PD), recession depth (RD), recession width (RW), clinical attachment level (CAL), keratinized tissue thickness (KTT), keratinized tissue width (KTW), and root coverage (RC) were assessed at the baseline as well as at three and six months post-surgery. Healing index (HI) were obtained in the second and third weeks post-surgery. Postoperative pain was assessed for the first seven days using a horizontal visual analog scale (VAS). Results No significant change was observed in PI, GI, or PD values in either the intergroup or the intragroup comparisons. A statistically significant decrease was observed in CAL, RD, and RW, and KTT increased in all groups at three and six months compared with the baseline. The control group had greater increases in KTW, KTT, and RC at three and six months. No significant difference was found in CAL or RD at the third and sixth months between the two groups. Healing was found to be similar for both groups in the second and third weeks post-surgery. The VAS values in the control group were higher than in the test group, especially at the second, fourth, fifth, and seventh days postoperatively. Conclusions CTG is superior to CGF with CAF for increasing KTT, KTW, and RC. CGF may be preferable due to decreased postoperative pain.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Surgical Flaps/transplantation , Connective Tissue/transplantation , Intercellular Signaling Peptides and Proteins/therapeutic use , Gingival Recession/surgery , Pain, Postoperative , Reference Values , Time Factors , Wound Healing , Blood Platelets , Periodontal Index , Dental Plaque Index , Reproducibility of Results , Treatment Outcome , Statistics, Nonparametric
5.
Acta cir. bras ; 35(2): e202000204, 2020. graf
Article in English | LILACS | ID: biblio-1100885

ABSTRACT

Abstract Purpose To investigate the effect of growth arrest-specific protein 6 (Gas6) on acute liver injury in mice and related mechanisms. Methods Thirty C57BL/6 (6-8 weeks old) mice were randomly divided into control, LPS/D-GalN, and LPS/D-GalN+Gas6 groups (10 mice in each group). The LPS/D-GalN group was intraperitoneally administered with LPS (0.25 mg/Kg) and D-GalN (400 mg/Kg) for 5h. The LPS/D-GalN+Gas6 group was intraperitoneally administered with rmGas6 one hour before intraperitoneal application of LPS/D-GalN. All subjects were sacrificed at 5 h for blood and tissue analysis. The expression of protein and mRNA was assessed by western blotting and RT-PCR, respectively. Results Compared with the control group, AST, ALT, IL-1β, TNF-α, IL-6 IL-10, MPO activity were increased in the LPS/D-GalN group. However, they were significantly inhibited by Gas6. Gas6 markedly suppressed the expression of apoptosis-related protein induced by LPS/D-GalN. Moreover, Gas6 attenuated the activation of the NF-κB signaling pathway in acute liver injury induced by LPS/D-GalN. Conclusions Gas6 alleviates acute liver injury in mice through regulating NF-κB signaling pathways. Gas6 can be a potential therapeutic agent in treating LPS/D-GalN-induced acute liver injury in the future.


Subject(s)
Animals , Male , Mice , Lipopolysaccharides/adverse effects , Apoptosis/drug effects , Intercellular Signaling Peptides and Proteins/pharmacology , Chemical and Drug Induced Liver Injury/drug therapy , Liver/drug effects , Anti-Inflammatory Agents/pharmacology , Intercellular Signaling Peptides and Proteins/therapeutic use , Drug Evaluation, Preclinical , Anti-Inflammatory Agents/therapeutic use
6.
Braz. oral res. (Online) ; 34: e034, 2020. tab, graf
Article in English | LILACS, BBO | ID: biblio-1100933

ABSTRACT

Abstract The aim of this split mouth, double blinded, randomized clinical trial was to evaluate the clinical efficacy of use of Plasma rich in growth factors (PRGF) as an adjunct to scaling and root planing (SRP) in the treatment of periodontal pockets. Twenty six patients (15 males, 11 females) diagnosed with generalized periodontitis with Pocket Depth > 5mm and plaque index score < 1.5, were randomly allocated by using computer generated random sequence, into two groups, one treated with intra-pocket application of PRGF adjunct to SRP and other with SRP alone. The clinical outcomes like pocket depth (PD), relative attachment level (RAL) and sulcus bleeding index (SBI) were assessed at baseline, 3 months and 6 months. Twenty two patients (44 sites) were analyzed at the end of 6 month follow-up, using SPSS 20.0v software. There was a significant statistical difference observed between both the groups favouring SRP +PRGF group in terms of PD (p = 0.007) and RAL (p = 0.021) at the end of 6 month follow-up. Also there was a statistical significant difference (< 0.001) at all time points compared to baseline, for all parameters in intra-group comparison. Moreover, the sites with PD>4mm necessitating further treatment after 6-month follow-up were significantly lesser for SRP+PRGF group. The use of PRGF technology in non-surgical periodontal therapy, by single intra-pocket application in to periodontal pockets as an adjunct to SRP, in chronic periodontitis patients, was found to be effective in reduction of pocket depth and gain in clinical attachment level.


Subject(s)
Humans , Male , Female , Adult , Periodontal Pocket/therapy , Dental Scaling/methods , Intercellular Signaling Peptides and Proteins/therapeutic use , Platelet-Rich Plasma , Time Factors , Periodontal Index , Double-Blind Method , Reproducibility of Results , Follow-Up Studies , Treatment Outcome , Periodontal Attachment Loss , Middle Aged
7.
Int. j. morphol ; 37(4): 1564-1571, Dec. 2019. tab
Article in Spanish | LILACS | ID: biblio-1040170

ABSTRACT

Las glándulas salivales humanas pueden ser gravemente lesionadas por la radioterapia utilizada contra neoplasias de cabeza y cuello, produciendo hiposialia y xerostomía, las cuales afectan la salud oral y sistémica, mermando la calidad de vida de la persona. Los tratamientos convencionales actuales están diseñados para disminuir los síntomas, sin actuar sobre los cambios fisiopatológicos que se dan a nivel glandular. Esta revisión intenta analizar aquellas terapias preventivas y/o curativas que están desarrollándose en el campo biomolecular y que tienen un futuro prometedor por sus características innovadoras: terapia génica, terapia con células madre y terapia con factores de crecimiento. Se evidencia un aporte adicional de la nanotecnología, la cual está mejorando las vías de aplicación de los tratamientos.


Human salivary glands can be seriously injured by the radiotherapy used against head and neck neoplasms, producing hyposialia and xerostomy, which affect oral and systemic health, diminishing the person's quality of life. Current conventional treatments are designed to reduce symptoms, without acting on the pathophysiological changes that occur at the glandular level. This review attempts to analyze those preventive and /or curative therapies that are developing in the biomolecular field and that have a promising future due to their innovative features: Gene therapy, stem cell therapy and growth factor therapy. An additional contribution of nanotechnology is evident, which is improving the routes of treatment application.


Subject(s)
Humans , Radiotherapy/adverse effects , Salivary Gland Diseases/prevention & control , Stem Cells/physiology , Genetic Therapy/methods , Intercellular Signaling Peptides and Proteins/therapeutic use , Radiation Injuries/prevention & control , Radiation-Protective Agents/therapeutic use , Salivary Gland Diseases/therapy , Salivary Glands/radiation effects , Xerostomia/prevention & control , Nanotechnology
8.
Arq. bras. oftalmol ; 82(1): 78-84, Jan.-Feb. 2019. tab
Article in English | LILACS | ID: biblio-973874

ABSTRACT

ABSTRACT The transparency and maintenance of corneal epithelial integrity are essential for its optical properties and, to preserve these characteristics, the epithelium undergoes continuous renewal. This renewal depends on the control of cell proliferation and differentiation mediated by mitogenic factors responsible for increasing mitoses and stimulating cellular migration. Cell-cell communication plays a pivotal role in epithelial healing process, and several cytokines and growth factors are involved in this process. Understanding the cross-talk and paracrine effects of these cytokines and growth factors released can help in the search for new therapeutic strategies to treat ocular surface diseases.


RESUMO A transparência e a manutenção da integridade epitelial da córnea são essenciais para suas propriedades ópticas e, para preservar tais características, o epitélio sofre renovação contínua. Essa renovação depende do controle da proliferação e diferenciação celular mediadas por fatores mitogênicos responsáveis pelo aumento das mitoses e estímulo à migração celular. A comunicação célula-célula desempenha um papel fundamental no processo de cicatrização epitelial, e várias citocinas e fatores de crescimento estão envolvidos neste processo. Compreender os efeitos cruzados e paracrinos dessas citocinas e fatores de crescimento liberados pode ajudar na busca de novas estratégias terapêuticas para o tratamento de doenças da superfície ocular.


Subject(s)
Humans , Wound Healing/physiology , Epithelium, Corneal/physiology , Intercellular Signaling Peptides and Proteins/therapeutic use , Cell Differentiation/physiology , Epithelium, Corneal/cytology , Corneal Diseases/therapy , Intercellular Signaling Peptides and Proteins/physiology , Cell Proliferation/physiology , Epithelial Cells/physiology , Fibroblasts/physiology
9.
Rev. cuba. hematol. inmunol. hemoter ; 34(1): 89-95, ene.-mar. 2018. ilus
Article in Spanish | LILACS, CUMED | ID: biblio-978414

ABSTRACT

La enfermedad pilonidal o fístula pilonidal es una afección que se presenta a lo largo del pliegue entre los glúteos, desde el hueso sacro hasta el ano. Esta afección involucra los folículos pilosos de la región presacra, los cuales penetran en el tejido celular subcutáneo y forman un quiste alrededor. Se presenta como una o varias fositas o depresiones de diámetro pequeño, puntiforme por la que emergen pelos. Como parte del tratamiento médico se describen medidas locales, la antibióticoterapia de amplio espectro y tratamiento quirúrgico, en el cual se describen técnicas de resección abiertas y cerradas. Se presenta el caso de una adolescente femenina de 16 años de edad, diagnosticada hace año y medio con una fístula pilonidal que requirió tratamiento con vitaminoterapia, medidas locales e intervención quirúrgica en tres ocasiones. En la última de ellas se produjo dehiscencia del sitio quirúrgico, escaso tejido de granulación y pobre cicatrización. Por tal motivo se decidió la aplicación de lisado de plaquetas en toda el área de la fístula a razón de 1 mL en días alternos, durante dos semanas, se continuó una aplicación semanal durante las 4 semanas siguientes hasta que se obtuvo el cierre total. La utilización del lisado de plaquetas favorece el tejido de granulación y la cicatrización en la fistula pilonidal(AU)


Intergluteal pilonidal disease or pilonidal fistula is a condition presenting along the cleft between the buttocks, which runs from the bone at the bottom of the spine (sacrum) to the anus. This condition involves the hair follicles of the presacral region, which penetrates into the subcutaneous tissue and forms a cyst around. It is presented as one or more pits or depressions of small diameter emerging punctuate by hairs. As part of medical treatment local measures, broad-spectrum antibiotic therapy and surgical treatment, which may be open and closed resection techniques, are described. We present a case of a 16- year- old female teenager, diagnosed a year and half ago, with a pilonidal fistula that required surgical treatment in 3 occasions, with local measures and vitamin therapy; dehiscence of the surgical site, poor tissue granulation and poor healing. It was applied platelet lysate throughout the area of the fistula at 1 mL alternate days, for two weeks, infiltration was continued for 4 weeks obtaining the total closure of the same. Therefore the use of platelet lysate promotes granulation tissue and scarring in pilonidal fistula(AU)


Subject(s)
Female , Adolescent , Platelet Activating Factor/therapeutic use , Rectal Fistula/therapy , Intercellular Signaling Peptides and Proteins/therapeutic use , Case Reports , Regenerative Medicine
10.
Arq. bras. cardiol ; 107(3): 271-275, Sept. 2016. tab
Article in English | LILACS | ID: lil-796038

ABSTRACT

Abstract Myocardial infarction is the most significant manifestation of ischemic heart disease and is associated with high morbidity and mortality. Novel strategies targeting at regenerating the injured myocardium have been investigated, including gene therapy, cell therapy, and the use of growth factors. Growth factor therapy has aroused interest in cardiovascular medicine because of the regeneration mechanisms induced by these biomolecules, including angiogenesis, extracellular matrix remodeling, cardiomyocyte proliferation, stem-cell recruitment, and others. Together, these mechanisms promote myocardial repair and improvement of the cardiac function. This review aims to address the strategic role of growth factor therapy in cardiac regeneration, considering its innovative and multifactorial character in myocardial repair after ischemic injury. Different issues will be discussed, with emphasis on the regeneration mechanisms as a potential therapeutic resource mediated by growth factors, and the challenges to make these proteins therapeutically viable in the field of cardiology and regenerative medicine.


Resumo O infarto do miocárdio representa a manifestação mais significativa da cardiopatia isquêmica e está associado a elevada morbimortalidade. Novas estratégias vêm sendo investigadas com o intuito de regenerar o miocárdio lesionado, incluindo a terapia gênica, a terapia celular e a utilização de fatores de crescimento. A terapia com fatores de crescimento despertou interesse em medicina cardiovascular, devido aos mecanismos de regeneração induzidos por essas biomoléculas, incluindo angiogênese, remodelamento da matriz extracelular, proliferação de cardiomiócitos e recrutamento de células-tronco, dentre outros. Em conjunto, tais mecanismos promovem a reparação do miocárdio e a melhora da função cardíaca. Esta revisão pretende abordar o papel estratégico da terapia, com fatores de crescimento, para a regeneração cardíaca, considerando seu caráter inovador e multifatorial sobre o reparo do miocárdio após dano isquêmico. Diferentes questões serão discutidas, destacando-se os mecanismos de regeneração como recurso terapêutico potencial mediado por fatores de crescimento e os desafios para tornar essas proteínas terapeuticamente viáveis no âmbito da cardiologia e da medicina regenerativa.


Subject(s)
Humans , Regeneration/physiology , Myocardial Ischemia/physiopathology , Myocardial Ischemia/therapy , Intercellular Signaling Peptides and Proteins/therapeutic use , Regenerative Medicine/methods , Neovascularization, Physiologic/physiology , Myocytes, Cardiac/physiology , Regenerative Medicine/trends , Heart/physiology
11.
Int. j. odontostomatol. (Print) ; 9(2): 289-294, ago. 2015. ilus
Article in Spanish | LILACS | ID: lil-764043

ABSTRACT

La mucositis es la reacción secundaria a la quimioterapia y/o radioterapia, existen múltiples opciones terapéuticas para tratar esta complicación, no se cuenta con un tratamiento definido por lo que el objetivo de esta revisión es el de agrupar las distintas maneras de abordar la mucositis oral y su efecto así como compartir la experiencia que se tiene en el Hospital General de México. Dentro de los tratamientos más utilizados se encuentra el empleo de fármacos protectores de mucosa, crioterapia, factores de crecimiento entre otros, el efecto deseado es retrasar la aparición de la lesión así como disminuir la severidad de las mismas, no todas las opciones se encuentran disponibles para el personal médico por lo que se deben de conocer las distintas opciones terapéuticas y la solidez científica con la que cuentan.


Mucositis is the secondary reaction to chemotherapy and / or radiotherapy, there are multiple therapeutic alternatives to treat this complication, there doesn't exist a specific therapy so the aim of this review is to coordinate the various ways of treating oral mucositis and its effect and to share the experience at the General Hospital of Mexico. Within the most widely used treatments is the use of mucosal protective drugs, cryotherapy, growth factors, among others, the main effect is to delay the onset of injury and decrease the severity of them, not all options are available for medical staff so they must know the different Iptherapeutic alternatives and the scientific soundness for each option.


Subject(s)
Humans , Stomatitis/therapy , Oral Hygiene , Radiotherapy/adverse effects , Stomatitis/etiology , Biological Products/therapeutic use , Cryotherapy , Intercellular Signaling Peptides and Proteins/therapeutic use , Drug-Related Side Effects and Adverse Reactions , Laser Therapy , Hospitals, General , Mexico , Neoplasms/complications
12.
Acta ortop. mex ; 28(5): 310-314, sep.-oct. 2014. ilus
Article in Spanish | LILACS | ID: lil-740975

ABSTRACT

Antecedentes: Las roturas bilaterales de tendones cuadricipitales son enfermedades de muy baja frecuencia. Las reparaciones quirúrgicas suelen ser los tratamientos más adecuados y exigen tiempos de recuperación de varios meses. Métodos: Presentamos el caso de un paciente con rotura bilateral de tendones cuadricipitales tras un traumatismo de baja energía, que fue tratado mediante sutura transpatelar quirúrgica reforzada con plasma rico en factores de crecimiento (PRGF-Endoret). Resultados: Los resultados a corto plazo evidenciaron una recuperación funcional y mediante imagen en poco más de dos meses. Conclusiones: La utilización de PRGF asociado a la cirugía habitual puede ayudar a la realización de una rehabilitación precoz.


Background: Bilateral quadriceps tendon tears are infrequent conditions. Surgical repairs are the most appropriate treatments and they involve several months of recovery. Methods: We report the case of a patient with bilateral quadriceps tendon tear resulting from low energy trauma. He was treated with surgical transpatellar suturing reinforced with plasma rich in growth factors (PRGF-Endoret). Results: Short-term results showed functional and radiological recovery at the two-months follow-up. The use of PRGF together with usual surgery may contribute to early rehabilitation.


Subject(s)
Aged , Humans , Male , Intercellular Signaling Peptides and Proteins/therapeutic use , Plasma , Tendon Injuries/therapy , Quadriceps Muscle , Rupture
13.
Article in Korean | WPRIM | ID: wpr-212483

ABSTRACT

Understanding of the pathophysiology of inflammatory bowel disease (IBD) is constantly evolving and, recently, a number of biologic agents have been developed. They selectively target specific molecule or pathways and correct the imbalance of the gut immune system. Among them, antibody to tumor necrosis factor (anti-TNF-alpha) is the first developed drugs, and it dramatically improved the IBD management. However, more than one-third of the patients do not respond to the drugs due to antibody formation. To increase treatment efficacy, enormous effort to develop novel anti-cytokines which can be an alternative to anti-TNF-alpha has been made. They are anti CD4+ T cell cytokine including interleukin (IL)-12/23 and IL-17 blockers, selective anti-adhesion molecule known as natalizumab, vedolizumab and alicaforsen, T-cell proliferation inhibitor, anti-inflammatory cytokine, immune stimulator, growth factor, and mitogen-activated protein kinase inhibitor. The efficacy and safety of each drugs are under investigation. Some drugs reported very promising data, however, others showed disappointing and different results. In addition, most of the trials were done in a very small number of patients, and there is no trial comparing to anti-TNF-alpha. The present paper reviews the action mechanism, short or long term efficacy and safety of variable drugs other than anti-TNF-alpha in IBD.


Subject(s)
Humans , Antibodies, Monoclonal/therapeutic use , Cell Migration Inhibition , Colony-Stimulating Factors/therapeutic use , Cytokines/antagonists & inhibitors , Genetic Therapy , Immunosuppressive Agents/therapeutic use , Inflammatory Bowel Diseases/drug therapy , Intercellular Signaling Peptides and Proteins/therapeutic use , Mitogen-Activated Protein Kinases/antagonists & inhibitors , Stem Cell Transplantation , Tumor Necrosis Factor-alpha/antagonists & inhibitors
14.
Braz. dent. j ; 22(6): 443-448, 2011.
Article in English | LILACS | ID: lil-622715

ABSTRACT

Large bone defects, congenital or caused by diseases, trauma or surgery, do not heal spontaneously and are usually a clinical challenge in the orthopedic and dental practices. A critical review concerning strategies to substitute lost bone or stimulate osteogenesis was undertaken. Pivotal concepts ranging from traditional bone grafting and use of biomaterials to local application of growth factors and gene therapy were addressed, including critical comments on the efficacy and safety, difficulties, advantages and disadvantages of each method. The most predictable results are still obtained with autogenous bone graft, despite the inconveniences of morbidity and limited availability of graft material. Satisfactory results have been reported for recombinant bone morphogenetic proteins (rhBMPs)-2 and -7, which distinguish for their osteoinductive property, the difficulty being the need for a degradable carrier that allows its continuous release in a rate compatible to that of new bone formation. Other bone growth factors are currently under evaluation in preclinical models of bone defects; however their efficacy is also dependent on the competence of a delivery strategy and on an appropriate delineation of “which one”, “which dose” and “when”. Parameters of efficiency and safety for gene therapy are still being established. In conclusion, given the variety of growth factors involved in the complex cascade of bone repair and the biological interactions between them, it remains a challenge to accomplish the ideal strategy to stimulate reparational bone formation in specific conditions of the medical as in the dental practices.


Defeitos ósseos de grandes dimensões, congênitos ou causados por doenças, traumas ou cirurgias, não se regeneram espontaneamente e são, no geral, um desafio para médicos e dentistas. O presente trabalho apresenta uma revisão crítica sobre estratégias para substituir tecido ósseo ou estimular a osteogênese reparacional. São apresentados conceitos relevantes relativos aos métodos tradicionais de enxertos/implantes ósseos e uso de biomateriais até a aplicação local de fatores de crescimento e a terapia gênica, incluindo comentários críticos sobre eficácia, segurança, dificuldades, vantagens e desvantagens de cada método. Os resultados mais previsíveis ainda são obtidos com enxertos ósseos autógenos, apesar das incoveniências de morbidade e disponibilidade limitada de material. Resultados satisfatórios têm sido relatados com o uso de proteínas ósseas morfogenéticas humanas recombinantes (rhBMPs)-2 e -7, que se distinguem pela capacidade de osteoindução, apesar da necessidade do uso combinado com um carreador biodegradável que permita sua liberação em um ritmo compatível com o da neoformação óssea. Outros fatores de crescimento ósseo estão presentemente em fase pré-clinica de avaliação e sua eficácia também depende de uma estratégia adequada de liberação, além da definição de parâmetros como “qual fator”, “em que dose” e “quando”. Ainda estão sendo estabelecidos os parâmetros de eficiência e segurança para aplicação da terapia gênica em defeitos ósseos. Concluindo, diante da grande variedade de fatores de crescimento envolvidos na complexa cascata do reparo ósseo e das interações que eles estabelecem, definir a melhor estratégia para estimular a formação óssea em situações específicas das práticas médica e odontológica permanece um desafio para cientistas e clínicos.


Subject(s)
Humans , Bone Diseases/surgery , Osteogenesis/physiology , Bone Transplantation , Biocompatible Materials/therapeutic use , Bone Substitutes/therapeutic use , Genetic Therapy , Intercellular Signaling Peptides and Proteins/therapeutic use
15.
Article in English | IMSEAR | ID: sea-135534

ABSTRACT

Treatment of delayed union, malunion, and nonunion is a challenge to the orthopaedic surgeons in veterinary and human fields. Apart from restoration of alignment and stable fixation, in many cases adjunctive measures such as bone-grafting or use of bone-graft substitutes are of paramount importance. Bone-graft materials usually have one or more components: an osteoconductive matrix, which acts as scaffold to new bone growth; osteoinductive proteins, which support mitogenesis of undifferentiated cells; and osteogenic cells, which are capable of forming bone in the appropriate environment. Autologous bone remains the “gold standard” for stimulating bone repair and regeneration, but its availability may be limited and the procedure to harvest the material is associated with complications. Bone-graft substitutes can either substitute autologous bone graft or expand an existing amount of autologous bone graft. We review the currently available bone graft and graft substitutes for the novel therapeutic approaches in clinical setting of orthopaedic surgery.


Subject(s)
Bone Development/physiology , Bone Regeneration/physiology , Bone Substitutes , Bone Transplantation/methods , Calcium Phosphates , Calcium Sulfate , Ceramics/therapeutic use , Durapatite , Genetic Therapy/methods , Humans , Intercellular Signaling Peptides and Proteins/therapeutic use , Mesenchymal Stem Cell Transplantation/methods , Orthopedic Procedures/methods , Polymers/therapeutic use
16.
Ciênc. rural ; 39(4): 1279-1286, jul. 2009. tab
Article in Portuguese | LILACS | ID: lil-519129

ABSTRACT

O plasma rico em plaquetas e o concentrado de plaquetas são fontes de diversos fatores de crescimento, com grande potencial terapêutico. Uma vez liberados dos grânulos alfa das plaquetas ativadas, esses fatores atuarão no sítio da lesão, estimulando a quimiotaxia, fibroplasia e angiogênese, melhorando assim a reparação tecidual. Embora esses componentes ricos em plaquetas sejam de fácil obtenção e de eficácia comprovada na medicina humana e odontologia, a utilização desses componentes na medicina veterinária é relativamente recente, necessitando ainda de estudos controlados. Neste artigo, os aspectos morfológicos das plaquetas, a ação dos fatores de crescimento e a utilização de componentes ricos em plaquetas na reparação tecidual de estruturas tendo-ligamentosas e osteo-articulares são revisados.


Platelet-rich plasma and platelet concentrates are involved in growing factors. Both have great therapeutic potential. When the alpha-granules are released by the active platelet, they act in the lesion site stimulating the chemotaxis, the fiberplasia and the angiogenesis. They improve the regeneration of the tissue. Although these rich platelet components are easy to obtain and efficiently to prove by medicine and dentistry, their use on vet medicine is recent. So, much more control studies need to be done. This article reviews morphological aspects of platelets, action of growing factors and use of components rich in platelet in wound healing tendons, ligaments and osteo-articular structures.


Subject(s)
Animals , Ligaments, Articular/injuries , Platelet-Rich Plasma , Intercellular Signaling Peptides and Proteins/therapeutic use , Tendon Injuries/therapy , Tendon Injuries/veterinary
17.
Braz. oral res ; 23(3): 275-280, 2009. ilus, tab
Article in English | LILACS | ID: lil-530264

ABSTRACT

A radiographic and histomorphometric study was conducted on the influence of autologous plasma rich in growth factors (PRGF) upon bone healing in surgically created defects in rabbits. Radiographically, bone regeneration was significantly greater with the use of PRGF after one month (p = 0.005), though no differences were recorded after the second month. In the histomorphometric analysis one month after surgery, the defects filled with autologous bone plus PRGF showed a greater percentage of neoformed bone (35.01 ± 5.31) than the control defects (22.90 ± 12.23), though the differences were not significant. Two months after surgery, the defects filled with autologous bone showed greater regeneration (46.04 ± 10.36 percent) than the control defects (30.59 ± 5.69 percent), though the differences were not significant. The application of PRGF in the bone defects produced in New Zealand rabbits exerted a limited effect on local bone formation.


Subject(s)
Animals , Male , Rabbits , Bone Regeneration/drug effects , Intercellular Signaling Peptides and Proteins/therapeutic use , Osteogenesis/drug effects , Platelet-Rich Plasma/chemistry , Tibia/surgery , Wound Healing/drug effects , Bone Transplantation , Tibia/pathology , Tibia
18.
Arq. bras. oftalmol ; 71(6,supl.0): 47-54, nov.-dez. 2008. tab
Article in English | LILACS | ID: lil-507474

ABSTRACT

Autologous serum has been used to treat dry eye syndrome for many years. It contains several growth factors, vitamins, fibronectin and other components that have been considered important for corneal and conjunctival integrity. Serum eye drops are usually prepared as an unpreserved blood solution. The serum is by nature well tolerated and its biochemical properties are somewhat similar to natural tears. Autologous serum eye drops have been reported to be effective for the treatment of severe dry eye-related ocular surface disorders (Sjõgren's syndrome), and also other entities such as superior limbic keratoconjunctivitis, graft-versus-host disease, Stevens-Johnson syndrome, ocular cicatricial pemphigoid, recurrent or persistent corneal erosions, neurotrophic keratopathy, Mooren's ulcer, aniridic keratopathy, filtering blebs after trabeculectomy, and post-keratorefractive surgery. The purpose of this study is to review the recently published literature on ocular surface diseases treated with human autologous serum eye drops.


O soro autólogo tem sido adotado como uma nova abordagem para tratar síndrome do olho seco porque contém vitaminas, alguns fatores de crecimento e fibronectina que são considerados importantes contribuintes para integridade corneana e conjuntival. Colírio de soro autólogo é produzido sem preservativo. O soro é não-alérgico e suas propriedades bioquímicas são similares à lágrima. O soro autólogo tópico tem sido relatado efetivo para o tratamento de olho seco grave relacionado a distúrbios da superfície ocular como na síndrome de Sjõgren, ceratoconjuntivite límbica superior, doença do enxerto versus hospedeiro, síndrome de Stevens-Johnson, procedimentos cerato-refrativos, erosão corneana persistente ou recorrente, ceratopatia neurotrófica, úlcera de Mooren, ceratopatia associada à aniridia, e bolhas filtrantes após trabeculectomia. O objetivo do presente estudo é revisar a literatura recentemente publicada sobre doenças da superficie ocular tratadas com soro autológo tópico.


Subject(s)
Humans , Blood Transfusion, Autologous , Conjunctival Diseases/drug therapy , Corneal Diseases/drug therapy , Ophthalmic Solutions/therapeutic use , Serum , Dry Eye Syndromes/drug therapy , Intercellular Signaling Peptides and Proteins/therapeutic use , Serum/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL